Moroctocog alfa

Drug Profile

Moroctocog alfa

Alternative Names: FuseNGO; Moroctocog Alfa (Af-cc); PF-05208756; PF-5208756; r-VIII SQ; Recombinant factor VIII SQ; ReFacto; Refacto AF; ReFacto AF; Xyntha

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Pfizer
  • Class Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 01 Aug 2015 Pfizer completes a phase I trial for Haemophilia A in China (IV, Infusion) (NCT02461992)
  • 14 Jul 2015 Launched for Haemophilia A in China (IV) before July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top